Management information from Tripep

Management information from Tripep

As previously announced The Board of Tripep's has come to a mutual understanding
with Tripep's CEO Jan Nilsson that he will leave the Company. During a
transitional stage Anders Vahlne, Head of Research and Development, will be the
acting CEO after Jan Nilsson. Anders Vahlne will take office on 1 April 2009.



For more information, please contact:

Anders Vahlne, CEO & Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se






About Tripep
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal® and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB. For more information, please refer to the
company's website:
www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.